Fig. 1
From: Tumour inhibitory activity on pancreatic cancer by bispecific nanobody targeting PD-L1 and CXCR4
Purification and identification of the nanobodies. a Purification of the nanobodies using a His-tag affinity chromatography column on an ÄKTA Start System. b SDS‒PAGE and Western blot analysis of the nanobodies (the cropped gel/blot are displayed here for better layout, and the full-length gels/blot are shown in Supplementary Fig. 1). Lane M, low molecular weight (MW) protein markers. Lane 1, BsNb PX4; Lane 2, Nb CXCR4; Lane 3, Nb PD-L1. c Q-TOF/LC‒MS to identify the complete MW of BsNb PX4